We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
Cap. Flow
+$34M
Cap. Flow %
12.86%
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45

Top Buys

Rank Stock Value
1
DTM icon
DT Midstream
DTM
+$1.85M
2
DK icon
Delek US
DK
+$898K
3
SMG icon
ScottsMiracle-Gro
SMG
+$843K
4
VLO icon
Valero Energy
VLO
+$783K
5
FMC icon
FMC
FMC
+$709K

Top Sells

Rank Stock Value
1
COR
Coresite Realty Corporation
COR
+$1.67M
2
XLRN
Acceleron Pharma
XLRN
+$601K
3
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$448K
5
TVTX icon
Travere Therapeutics
TVTX
+$434K

Sector Composition

Rank Sector Weight
1 Real Estate 22.39%
2 Healthcare 18.38%
3 Energy 15.88%
4 Materials 14.07%
5 Utilities 13.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMTI
276
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$172K 0.07%
12,313
+7,981
+184% +$157K
ALLO icon
277
Allogene Therapeutics
ALLO
$573M
$171K 0.06%
11,487
+3,108
+37% +$54.8K
CUE icon
278
Cue Biopharma
CUE
$127M
$171K 0.06%
504
-17
-3% -$6.57K
KOD icon
279
Kodiak Sciences
KOD
$2.52B
$171K 0.06%
2,013
-485
-19% -$49.3K
KRON
280
DELISTED
Kronos Bio
KRON
$171K 0.06%
12,548
+4,422
+54% +$69.2K
AMRS
281
DELISTED
Amyris Inc.
AMRS
$171K 0.06%
31,527
+17,947
+132% +$168K
AGEN
282
Agenus
AGEN
$275M
$170K 0.06%
2,691
+584
+28% +$46K
IGMS
283
DELISTED
IGM Biosciences
IGMS
$170K 0.06%
5,787
+3,574
+162% +$178K
MCRB icon
284
Seres Therapeutics
MCRB
$46.5M
$170K 0.06%
1,019
+504
+98% +$80.1K
OLMA icon
285
Olema Pharmaceuticals
OLMA
$1.01B
$170K 0.06%
18,150
+11,036
+155% +$229K
RNAC icon
286
Cartesian Therapeutics
RNAC
$225M
$170K 0.06%
1,738
+324
+23% +$34.9K
RVMD icon
287
Revolution Medicines
RVMD
$39.1B
$170K 0.06%
6,746
+596
+10% +$16.8K
AFMD
288
DELISTED
Affimed
AFMD
$169K 0.06%
3,059
+517
+20% +$31.9K
ALGS icon
289
Aligos Therapeutics
ALGS
$26.3M
$169K 0.06%
568
+295
+108% +$108K
CLDX icon
290
Celldex Therapeutics
CLDX
$2.79B
$169K 0.06%
4,382
-3,483
-44% -$152K
RCUS icon
291
Arcus Biosciences
RCUS
$3.4B
$169K 0.06%
4,179
-4,485
-52% -$174K
VXRT
292
DELISTED
Vaxart
VXRT
$169K 0.06%
26,883
+2,552
+10% +$17.4K
ZYME icon
293
Zymeworks
ZYME
$1.66B
$169K 0.06%
10,324
+4,727
+84% +$98.6K
DICE
294
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$169K 0.06%
+6,683
New +$196K
FMTX
295
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$169K 0.06%
11,902
+3,143
+36% +$54.4K
NTLA icon
296
Intellia Therapeutics
NTLA
$1.52B
$168K 0.06%
1,425
-994
-41% -$125K
STRO icon
297
Sutro Biopharma
STRO
$393M
$168K 0.06%
1,131
+24
+2% +$4.3K
CNTA
298
DELISTED
Centessa Pharmaceuticals
CNTA
$167K 0.06%
+14,798
New +$199K
CRSP icon
299
CRISPR Therapeutics
CRSP
$4.68B
$167K 0.06%
2,203
+559
+34% +$48.8K
RGNX icon
300
Regenxbio
RGNX
$615M
$167K 0.06%
5,112
-548
-10% -$18.7K
10 11
12
13 14

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.

By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.

  • Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
  • Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
  • Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
  • Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
  • Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
  • Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
  • Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.